Sigyn Therapeutics has introduced CardioDialysis, a medical device designed to reduce major adverse cardiovascular events through continuous blood purification. Cardiovascular disease remains the leading cause of death worldwide, with current treatments offering limited protection against heart attacks, strokes, and related complications.
While statin drugs reduce major adverse cardiovascular events by approximately 25%, lipoprotein apheresis technologies have demonstrated 75-95% reductions according to the American Heart Association. However, these advanced treatments face significant adoption barriers due to complex multi-component systems requiring specialized facilities. The Kaneka LIPOSORBER, an FDA-approved lipoprotein apheresis procedure, illustrates these limitations with its requirement for plasma separation columns, multiple cartridges, custom tubing sets, various pumps, and replacement fluids.
CardioDialysis represents a technological breakthrough by integrating plasma separation and therapeutic adsorption within a single device deployable on existing dialysis machines. This approach enables continuous broad-spectrum clearance of both inflammatory and pathogenic molecules from the entire bloodstream. Unlike the LIPOSORBER system, which is available at fewer than 60 specialized centers in the United States, CardioDialysis can potentially be deployed in more than 5,000 hospitals and 7,500 dialysis clinics nationwide.
The device's simplified design eliminates the need for replacement fluids, additional pumps, and auxiliary components while addressing a broader range of cardiovascular disease targets with greater processing efficiency. This accessibility improvement could dramatically expand treatment availability for patients at risk of cardiovascular events.
Given that 15-20% of major adverse cardiovascular events result in death, successful clinical advancement of CardioDialysis could save thousands of lives annually. The technology represents a significant advancement in subtractive medicine, overcoming limitations of single-target drugs by simultaneously reducing inflammatory mediators and cholesterol-transporting lipoproteins that contribute to cardiovascular disease progression.
Sigyn Therapeutics' development pipeline includes additional blood purification technologies such as ImmunePrep for cancer immunotherapy optimization, ChemoPrep for targeted chemotherapy delivery, and ChemoPure for chemotherapy toxicity reduction. More information about the company's technologies is available at https://www.SigynTherapeutics.com.
